FDA de­ci­sion on Sarep­ta’s Duchenne gene ther­a­py could come ear­li­er than ex­pect­ed

Sarep­ta Ther­a­peu­tics’ chief sci­en­tist sug­gest­ed that the FDA was ahead of sched­ule in re­view­ing the com­pa­ny’s ap­pli­ca­tion to ex­pand the la­bel of its Duchenne mus­cu­lar …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER